Measures Open for Public Comment
The AUA is conducting a survey seeking comments on revised measures relating to shared decision making and prostate-specific antigen (PSA) screening for use in quality improvement and accountability programs. A technical expert panel (TEP) was recently convened to identify and define new measures, which were presented at a CMS Spotlight Series event in June and July 2017. Many key stakeholders, including representatives from family medicine, internal medicine, oncology, geriatrics, and insurance, participated in the event and provided important feedback on the draft measures. The comment period begins on September 26, 2017 and will close on November 6, 2017 at midnight. All comments are welcome and will be compiled and shared with the TEP for consideration. Thank you in advance for your feedback.
View the Shared Decision Making Before Prostate Specific Antigen (PSA) Screening Quality Measures [pdf]